Arie Bellde­grun and the crew at Vi­da reap a $600M har­vest for fund II — and they've got LA in their sights

This is Arie Bellde­grun’s time.

A lit­tle more than a year ago we were talk­ing about his $300 mil­lion raise for his lat­est start­up Al­lo­gene, now in the race to pro­duce the world’s first off-the shelf CAR-T af­ter sell­ing the cur­rent per­son­al­ized CAR-T leader to Gilead — and reap­ing a per­son­al for­tune along the way. Months lat­er he and close as­so­ciate David Chang were rack­ing up a then record-set­ting IPO, gain­ing an­oth­er $324 mil­lion along the way.

Weeks ago the con­ver­sa­tion fo­cused on his new com­mer­cial re­al es­tate de­vel­op­ment firm, a joint ven­ture with plans to build a string of be­spoke biotech cen­ters in hubs around the world — start­ing with a hard blue­print in Boston’s Sea­port dis­trict.

To­day, the news cen­ters on a $600 mil­lion raise for his in­vest­ment group Vi­da Ven­tures — which he co-found­ed with a group of ex­pe­ri­enced VC ex­ecs with plans to dou­ble down on a ros­ter of new biotech star­tups look­ing to break new drug ground of their own. In less than 2 years he and his crew has now raised about a bil­lion dol­lars, adding spe­cial plans to help cre­ate a new biotech hub in Los An­ge­les.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER